儿童药物敏感结核一线治疗药物的有效性与药代动力学暴露:系统综述与荟萃分析
该系统综述与荟萃分析检索2010至2021年文献,纳入12篇疗效分析和18篇药代动力学分析,涉及1830名儿童。结果显示82%获得良好结局,但儿童在WHO推荐剂量下利福平、吡嗪酰胺和乙胺丁醇暴露低于成人,≤6岁儿童和HIV感染儿童利福平暴露更低。
要点
- 儿童药物敏感结核治疗良好结局平均为82%(范围25%-95%)。
- WHO推荐剂量下儿童利福平、吡嗪酰胺和乙胺丁醇暴露低于成人。
- ≤6岁儿童和HIV感染儿童利福平暴露分别低35%。
核心结论
- 儿童药物敏感结核治疗结局变异大,平均82%获得良好结局。
- 儿童药物暴露低于成人,年幼儿童和HIV感染儿童利福平暴露不足。
- 需要标准化儿科药代动力学研究和个体患者数据分析及安全性评估以指导最佳剂量。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、EMBASE、CENTRAL和试验注册库2010至2021年文献。
- 纳入年龄<18岁、接受利福平、吡嗪酰胺、异烟肼和乙胺丁醇治疗药物敏感结核的儿童研究。
- 共鉴定304项研究,46篇符合全文审查,12篇纳入疗效分析,18篇纳入药代动力学分析。
- 疗效分析共纳入1830名儿童。
- 系统综述方案在PROSPERO预注册(编号CRD42021274222)。
主要发现
- 1830名儿童中82%获得良好结局(范围25%-95%)。
- WHO推荐剂量下,儿童利福平、吡嗪酰胺和乙胺丁醇暴露低于成人。
- ≤6岁儿童利福平AUC为14.4(95%CI 9.9-18.8)μg·h/mL,较年长儿童的22.0(95%CI 13.8-30.1)μg·h/mL低35%。
- HIV感染儿童利福平AUC为17.3(95%CI 11.4-23.2)μg·h/mL,较HIV阴性儿童的26.5(95%CI 21.3-31.7)μg·h/mL低35%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 异质性和小样本量是主要局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal doses of first-line drugs for treatment of drug-susceptible tuberculosis in children and young adolescents remain uncertain. We aimed to determine whether children treated using World Health Organization-recommended or higher doses of first-line drugs achieve successful outcomes and sufficient pharmacokinetic (PK) exposures. METHODS: Titles, abstracts, and full-text articles were screened. We searched PubMed, EMBASE, CENTRAL, and trial registries from 2010 to 2021. We included studies in children aged <18 years being treated for drug-susceptible tuberculosis with rifampicin (RIF), pyrazinamide, isoniazid, and ethambutol. Outcomes were treatment success rates and drug exposures. The protocol for the systematic review was preregistered in PROSPERO (no. CRD42021274222). RESULTS: Of 304 studies identified, 46 were eligible for full-text review, and 12 and 18 articles were included for the efficacy and PK analyses, respectively. Of 1830 children included in the efficacy analysis, 82% had favorable outcomes (range, 25%-95%). At World Health Organization-recommended doses, exposures to RIF, pyrazinamide, and ethambutol were lower in children than in adults. Children ≤6 years old have 35% lower areas under the concentration-time curve (AUCs) than older children (mean of 14.4 [95% CI 9.9-18.8] vs 22.0 [13.8-30.1] μg·h/mL) and children with human immunodeficiency virus (HIV) had 35% lower RIF AUCs than HIV-negative children (17.3 [11.4-23.2] vs 26.5 [21.3-31.7] μg·h/mL). Heterogeneity and small sample sizes were major limitations. CONCLUSIONS: There is large variability in outcomes, with an average of 82% favorable outcomes. Drug exposures are lower in children than in adults. Younger children and/or those with HIV are underexposed to RIF. Standardization of PK pediatric studies and individual patient data analysis with safety assessment are needed to inform optimal dosing.
引用
- Solans BP, Béranger A, Radtke K, et al. Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2023. PMID: 36609692. doi:10.1093/cid/ciac973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。